Current Studies:
-
Description: a study to evaluate the immunogenicity and safety of an investigational varicella vaccine compared with Varivax, administered as a first dose to healthy children 12 to 15 months of age.
Qualifications:
Participants who are healthy as determined by medical evaluation including medical history
A male or female between, and including, 12 to 15 months of age (i.e., from the day
of 1-year birthday until the day before 16 months of age) at the time of the
administration of study interventions.Participant who previously received the primary series of PCV (Pneumococcal Conjugate Vaccine) in the first year
of life with last dose at least 60 days prior to study entry.
Participants will also be compensated for time, travel, and participation. This gives participants the opportunity to receive study-related treatment and medication at no cost.
-
Description: A study to evaluate the immunogenicity and safety of an investigational pneumococcal conjugate vaccine (PCV21) compared with Prevnar 20, administered as a primary series to healthy infants approximately 2 months of age.
Qualifications:
Participants who are healthy as determined by medical evaluation including medical history and physical examination
A male or female aged 42 to 89 days on the day of inclusion
Born at full term (≥ 37 weeks) with a birth weight ≥ 2.5 kg, or born after 28 weeks through 36 weeks with a birth weight ≥ 1.5 kg
Participant who has not previously received vaccination against S. pneumoniae, diphtheria, tetanus, pertussis, Haemophilus influenzae type b, or poliovirus.
Participants will also be compensated up to $1085 for time, travel, and participation. This gives participants the opportunity to receive study-related treatment and medication at no cost.
-
Description: The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine.
Qualifications:
Participants between the ages of 6 to <17 of age.
Must have a history and diagnosis of migraine with or without aura
Have a history of migraine attacks for more than 6 months
Reports at least 2 and no more than 8 moderate-to-severe migraine attacks per month in the 2 months prior to screening
Duration of a typical untreated migraine attack (excluding sleep) is greater than or equal to 3 hours
Participant must be able to swallow a tablet
For participants taking migraine preventive medication, treatment regimen is stable and has been taken for at least 3 months prior to screening
Participants must weigh at least 15 kilograms (kg)
Participants will also be compensated for time, travel, and participation. This gives participants the opportunity to receive study-related treatment and medication at no cost.
-
Description: The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine.
Qualifications:
Participants must have completed the Pediatric & Adolescent Migraine Study I.
Participants must weigh at least 15 kilograms (kg)
Participants will also be compensated for time, travel, and participation. This gives participants the opportunity to receive study-related treatment and medication at no cost.
-
Description: The main purpose of this study is to evaluate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine.
Qualifications:
Participants between the ages of 6 to 17 years of age.
Have a diagnosis of migraine with or without aura with a history of migraine headaches of at least 6 months prior to screening.
Have a history of 4-14 headache days per month, of which at least 4 are migraine headache days, and with at least 2 migraine attacks per month
Have received age-appropriate immunizations.
Are males and females who agree to abide by the reproductive and contraceptive requirements.
Participants will also be compensated for time, travel, and participation. This gives participants the opportunity to receive study-related treatment and medication at no cost.
-
Description: The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age.
Qualifications:
Participants between the ages of 12 to 17 years of age.
Have a diagnosis of chronic migraine with a history of at least 3 months prior to screening.
Have a frequency of at least 15 headache days during prospective baseline period of which at least 8 must have the features of migraine.
Have at least 1 headache-free day per 30-day period during prospective baseline period.
Have received age-appropriate immunizations.
Are males and females who agree to abide by the reproductive and contraceptive requirements.
Participants will also be compensated for time, travel, and participation. This gives participants the opportunity to receive study-related treatment and medication at no cost.
-
Description: A study to evaluate the safety and efficacy of various investigational interventions for Chronic Weight Management in Adult Participants with Obesity or Overweight.
Qualifications:
Participants age between 18 to 75 years of age.
BMI ≥27 kilograms per square meter (kg/m²)
Have a clinical diagnosis of Type 2 Diabetes for at least 6 months prior to screening
Have an HbA1c between 7% and 10.5%
Are males and females who agree to abide by the reproductive and contraceptive requirements
Participants will also be compensated for time, travel, and participation. This gives participants the opportunity to receive study-related treatment and medication at no cost.
-
Description: a study to evaluate the safety, tolerability, and immunogenicity of an updated COVID-19 vaccine (BNT162b2 LP.8.1) administered as a single dose to children 5 through 11 years of age who are considered at high risk for severe COVID-19
Qualifications:
Participants who are medically stable with at least 1 underlying medical condition that increases the risk of severe COVID-19 (such as asthma, diabetes, obesity, or heart conditions)
A male or female between, and including, 5 through 11 years of age at the time of enrollment
Participant who has not had a confirmed COVID-19 infection or received a COVID-19 vaccine within the past 5 months (150 days) prior to study enrollment
Participants will also be compensated for time, travel, and participation. This gives participants the opportunity to receive study-related treatment and medication at no cost.
-
Description: A study to evaluate the safety and immune response of an investigational chickenpox (varicella) vaccine compared to the standard chickenpox vaccine, administered as a first dose to healthy toddlers 12 to 15 months of age. Participants will also receive other routine childhood vaccinations (MMR and Hepatitis A) during the study.
Qualifications:
Healthy male or female toddlers established by medical history and clinical examination.
Between, and including, 12 to 15 months of age (from the day of their 1st birthday until the day before they turn 16 months) at the time of vaccination.
Participants who have not previously received a vaccine for measles, mumps, rubella, hepatitis A, or chickenpox (varicella).
Participants with no history of chickenpox disease.
Participants will also be compensated up to $725 for time, travel, and participation. This gives participants the opportunity to receive study-related vaccinations and medical assessments at no cost.
-
Description: A study to evaluate the efficacy and safety of an investigational medication (tirzepatide) compared to a placebo for weight management in adolescents 12 to 17 years of age living with obesity and weight-related health conditions. Participants will also receive a health promotion and lifestyle program, including counseling on healthy dietary patterns and physical activity, throughout the study.
Qualifications:
Male or female adolescents 12 to 17 years of age (inclusive) at the time of signing informed consent.
Diagnosed with obesity (BMI ≥95th percentile for age and sex).
Must have at least 2 of the following weight-related conditions: high blood pressure (hypertension), prediabetes, or high triglycerides.
History of at least one unsuccessful dietary effort to lose weight.
Participants who do not have Type 1 or Type 2 diabetes.
Participants who have not taken medication for weight loss or diabetes (including metformin) within the last 180 days.
Participants will also be compensated for time, travel, and participation. This gives participants the opportunity to receive study-related investigational medication or placebo and medical assessments at no cost.
Other Studies:
Major Depressive Disorder I Study
Description: A study to evaluate the efficacy and safety of Bupropion Hydrobromide in Adolescents and Children with Major Depressive Disorder.
Qualifications:
Participants who are aged ≥7 to <18 years.
Meet diagnostic criteria for MDD
Have current depressive episode of at least 4 weeks in duration as noted in the participant's history
Are on stable doses for allowed medication for a period of 30 days prior to visit 2 and not expected to change during the study and follow-up periods.
Participants will also be compensated for time, travel, and participation. This gives participants the opportunity to receive study-related treatment and medication at no cost.
Major Depressive Disorder II Study (Extension)
Description: A study to evaluate the safety and tolerability of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder
Qualifications:
Participants who successfully completed the Major Depressive Disorder I study.
Are males and females of childbearing potential who agree to use adequate contraception methods during study.
Meet diagnostic criteria for MDD
Are on stable doses for allowed medication for a period of 30 days prior to the Transition Visit and not expected to change during the study and follow-up periods.
Participants will also be compensated for time, travel, and participation. This gives participants the opportunity to receive study-related treatment and medication at no cost.